Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Celcuity is expanding its Phase 3 VIKTORIA-2 trial of gedatolisib to include endocrine-sensitive patients with HR+/HER2- advanced breast cancer. The trial will now evaluate the safety and efficacy of gedatolisib in combination with palbociclib and letrozole for endocrine-sensitive patients, in addition to the existing endocrine-resistant cohort.
Key figures
- Drug Name
- gedatolisib
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.